• 011-26907444
  • raghava@iiitd.ac.in

Browse result page of AntiTbPdb

The total number entries retrieved from this search are 550
IDNameSequenceN-Terminal ModificationC-Terminal ModificationChemical ModificationLinear/CyclicLengthChiralityNatureSourceOriginSpeciesStrainInhibition ConcentrationIn vitro/ In vivoCell LineIntracellular InhibitionCytotoxicityAnimal ModelEffective Dose in model organismImmune ResponceMechanism of ActionTargetCombination TherapyOther ActivitiesYear of PublicationPubmed ID/ Patent No.
antitb_1448A2-Rv2957 SIIIPTLNV FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv2958 Mycobacterium tuberculosisMycobacterium tuberculosis Rv2958 NANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1449A2-Rv0447 VLAGSVDEL FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv0447 Mycobacterium tuberculosisMycobacterium tuberculosis Rv0447NANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1450A24-TB10.4 IMYNYPAML FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv0447 Mycobacterium tuberculosisMycobacterium tuberculosis Rv0447NANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1451A24-Ag85B WYYQSGLSI FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Ag85B Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1452A24-Ag85B FLTSELPQW FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Ag85B Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1453A24-Ag85B IYAGSLSAL FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Ag85B Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1454A24-ESAT6 AYQGVQQKW FreeFreeNoneLinear9LNAProtein derivedMTB derived protein ESAT6 Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1455A24-ESAT6 ELNNALQNL FreeFreeNoneLinear9LNAProtein derivedMTB derived protein ESAT6 Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1456A24-Rv2958 KYIAADRKI FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv2958 Mycobacterium tuberculosisMycobacterium tuberculosis Rv2958 NANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1457A24-Rv2957 PYNLRYRVL FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv2958 Mycobacterium tuberculosisMycobacterium tuberculosis Rv2958 NANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1458A24-Rv0447 KYIFPGGLL FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv0447 Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1459A3001-TB10.4 QIMYNYPAM FreeFreeNoneLinear9LNAProtein derivedMTB derived protein TB10.4 Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1460A3001-TB10.4 LVRAYHAMS FreeFreeNoneLinear9LNAProtein derivedMTB derived protein TB10.4 Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1461A3001-Rv2957 IVLVRRWPK FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv2957Mycobacterium tuberculosisMycobacterium tuberculosis Rv2957NANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1462A3002-TB10.4 QIMYNYPAM FreeFreeNoneLinear9LNAProtein derivedMTB derived protein TB10.4 Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1463A3002-TB10.4 IMYNYPAML FreeFreeNoneLinear9LNAProtein derivedMTB derived protein TB10.4 Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1464A3002-TB10.4 AMEDLVRAY FreeFreeNoneLinear9LNAProtein derivedMTB derived protein TB10.4 Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1465A3002-ESAT6 AMASTEGNV FreeFreeNoneLinear9LNAProtein derivedMTB derived protein ESAT6 Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1466A3002-Rv2958 SARLAGIPY FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv2958 Mycobacterium tuberculosisMycobacterium tuberculosis Rv2958 NANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1467A3002-Rv0447 RMWELYLAY FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv0447 Mycobacterium tuberculosisMycobacterium tuberculosis Rv2958 NANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1468A68-TB10.4 HAMSSTHEA FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv0447 Mycobacterium tuberculosisMycobacterium tuberculosis Rv0447NANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1469A68-TB10.4 ANTMAMMAR FreeFreeNoneLinear9LNAProtein derivedMTB derived protein TB10.4 Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1470A68-Ag85B LPQWLSANR FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Ag85B Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1471A68-Ag85B WGAQLNAMK FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Ag85B Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1472A68-Rv2958 AAPEPVARR FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv2958Mycobacterium tuberculosisMycobacterium tuberculosis Rv2958 NANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1473A68-Rv2957 LVYGDVIMR FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv2957Mycobacterium tuberculosisMycobacterium tuberculosis Rv2957NANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1474A68-Rv0447 AASAAIANR FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Rv0447Mycobacterium tuberculosisMycobacterium tuberculosis Rv0447NANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1475B58-Ag85B QTYKWETFL FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Ag85B Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1476Cw07-Ag85B ANNTRLWVY FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Ag85B Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1478Lariatin AGSQLVYRWVGHSNVIKGPNANAAlpha carbon of glutamine form amide bond with first glycine and gamma carbon of glutamine involved in side chain formationCyclic18DCationicNaturalDerived from Rhodococcusjostii K01‐B0171Mycobacterium tuberculosisMycobacterium tuberculosis RvMIC = 0.39 mg/Lin vitroNANANANA NANAInhibit cell wall biosynthesisNANANA201525681127
antitb_1479Dihydromycoplanecin A (DHMP A)not availableNANANABranched cyclic0DCationicNaturalDerived from ActinoplanesawajinensisMycobacterium tuberculosisMycobacterium tuberculosis RvIC50= 0.0125-25mg/ml in vitroNANANANA NANANANANANA201525681127
antitb_1480Dihydromycoplanecin A (DHMP A)not availableNANANABranched cyclic0DCationicNaturalDerived from ActinoplanesawajinensisMycobacterium tuberculosisMycobacterium tuberculosis RvIC90= 0.05 μg/mLin vitroNANANANA NANANANANANA201525681127
antitb_1486Pitipeptolides Anot availableNANANABranched cyclic0DCationicNaturalDerived from Cyanobacterium Lyngbya majusculaMycobacterium tuberculosisMycobacteria smegmatis ATCC 25177Reduction in zone of growth to 25 mm at 100 μg conc.LoVo cancer cells NAIC50= 2.25 μg/ml for M.Smegmatis ATCC 25177 NA NANANANANANA201525681127
antitb_1487Pitipeptolides Anot availableNANANABranched cyclic0DCationicNaturalDerived from Cyanobacterium Lyngbya majusculaMycobacterium tuberculosisMycobacteria smegmatis ATCC 25177Reduction in zone of growth to 10 mm at 25 μgLoVo cancer cells NAIC50= 2.25μg/ml for M.Smegmatis ATCC 25177 NA NANANANANANA201525681127
antitb_1488Pitipeptolides Anot availableNANANABranched cyclic0DCationicNaturalDerived from Cyanobacterium Lyngbya majusculaMycobacterium tuberculosisMycobacteria smegmatis ATCC 35818Reduction in zone of growth to 15 mm at 100 μgLoVo cancer cells NAIC50= 1.95 μg/ml for m.Smegmatis ATCC35818NA NANANANANANA201525681127
antitb_1489Pitipeptolides Anot availableNANANABranched cyclic0DCationicNaturalDerived from Cyanobacterium Lyngbya majusculaMycobacterium tuberculosisMycobacteria smegmatis ATCC 35818Reduction in zone of growth to 9 mm at 25 μgLoVo cancer cells NAIC50= 1.95 μg/ml for m.Smegmatis ATCC35818NA NANANANANANA201525681127
antitb_1490Pitipeptolides Anot availableNANANABranched cyclic0DCationicNaturalDerived from Cyanobacterium Lyngbya majusculaMycobacterium tuberculosisMycobacteria smegmatis ATCC 25177Reduction in zone of growth to 30 mm at 100 μgLoVo cancer cells NAIC50= 2.25 μg/ml for M.Smegmatis ATCC 25177 NA NANANANANANA201525681127
antitb_1491Pitipeptolides Anot availableNANANABranched cyclic0DCationicNaturalDerived from Cyanobacterium Lyngbya majusculaMycobacterium tuberculosisMycobacteria smegmatis ATCC 25177Reduction in zone of growth to 15 mm at 25 μgLoVo cancer cells NAIC50= 2.25μg/ml for M.Smegmatis ATCC 25177 NA NANANANANANA201525681127
antitb_1492Pitipeptolides Anot availableNANANABranched cyclic0DCationicNaturalDerived from Cyanobacterium Lyngbya majusculaMycobacterium tuberculosisMycobacteria smegmatis ATCC 35818Reduction in zone of growth to 15 mm at 100 μgLoVo cancer cells NAIC50= 1.95 μg/ml for m.Smegmatis ATCC35818NA NANANANANANA201525681127
antitb_1493Pitipeptolides Anot availableNANANABranched cyclic0DCationicNaturalDerived from Cyanobacterium Lyngbya majusculaMycobacterium tuberculosisMycobacteria smegmatis ATCC 35818Reduction in zone of growth to 10 mm at 25 μgLoVo cancer cells NA IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 NA NANANANANANA201525681127
antitb_1494Lacticin 3147not availableNANANABranched cyclic0DCationicNaturalDerived from Lactococcuslactis Mycobacterium tuberculosisMycobacterium tuberculosis H37 RaIC90= 7.5 mg/ml (±0.36)in vitroNANANANA NANAInhibit biosynthesis of peptidoglycan and form pores in bacterial membraneNANANA201525681127
antitb_1495Lacticin 3148not availableNANANABranched cyclic0DCationicNaturalDerived from Lactococcuslactis Mycobacterium tuberculosisMycobacteria kansasii CIT11/06 IC90= 60 mg/ml (±0.75)in vitroNANANANA NANAInhibit biosynthesis of peptidoglycan and form pores in bacterial membraneNANANA201525681127
antitb_1497Nisin Anot availableNANANABranched cyclic0DCationicNaturalDerived from Lactococcus lactis Mycobacterium tuberculosisMycobacterium tuberculosis H37 RaIC90= >60mg/ml (±0.18)in vitroNANANANA NANAInhibit biosynthesis of peptidoglycan and form pores in bacterial membraneNANANA201525681127
antitb_1498Nisin Anot availableNANANABranched cyclic0DCationicNaturalDerived from Lactococcuslactis Mycobacterium tuberculosisMycobacteria kansasii CIT11/06 IC90= 60 mg/ml (±0.13)in vitroNANANANA NANAInhibit biosynthesis of peptidoglycan and form pores in bacterial membraneNANANA201525681127
antitb_1500Sansanmycins A (Ssa)not availableNANANABranched cyclic0DCationicNaturalDerived from Streptomyces speciesMycobacterium tuberculosisMycobacterium tuberculosis H37RvIC50= 16 μg/mlin vitroNANANANA NANAInhibit the MraY translocase present in the bacterial cell membraneNANAAntibacterial against E.coli, S.aureus, bacillus, pseudomonas201525681127
antitb_1501Sansanmycins A (Ssa)not availableNANANABranched cyclic0DCationicNaturalDerived from Streptomyces speciesMycobacterium tuberculosisMycobacterium tuberculosis 2199IC50= 32 μg/mlIn vitroNANANANA NANAInhibit the MraY translocase present in the bacterial cell membraneNANAAntibacterial against E.coli, S.aureus, bacillus, pseudomonas201525681127
antitb_1502Cyclomarin Anot availableNANANABranched cyclic0DCationicNaturalDerived from Streptomyces speciesMycobacterium tuberculosisMycobacterium tuberculosis H37RvIC50= 0.3mg/mlin vitroNANANANA NAChange the clp1subunit of casinolytic protease by allosteric bindingNANAAntibacterial against E.coli, S.aureus, bacillus, pseudomonas201525681127
antitb_1503Massetolide Anot availableNANANABranched cyclic0DCationicNaturalDerived from Pseudomonas fluorescens SS101Mycobacterium tuberculosisMycobacterium tuberculosis h37RVMIC = 5 mg/mlin vitroNANANANA NAinterfere with bacterial cell wall biosynthesisNANAAntibacterial against E.coli, S.aureus, bacillus, pseudomonas201525681127
antitb_1504Visconsinnot availableNANANABranched cyclic0DCationicNaturalDerived from Pseudomonas speciesMycobacterium tuberculosisMycobacterium avium intercellularaeMIC = 10 mg/mlin vitroNANANANA NAinterfere with bacterial cell wall biosynthesisNANAAntibacterial against E.coli, S.aureus, bacillus, pseudomonas201525681127
antitb_1505Bacitracinnot availableNANANABranched cyclic0DCationicNaturalDerived from Bacillus subtilisMycobacterium tuberculosisMycobacterium tuberculosis H37RvMIC = 130mg/mlin vitroNANANANA NANAinhibit bacterial cell wall synthesisNANAAntibacterial against E.coli, S.aureus, bacillus, pseudomonas201525681127